Login to Your Account

Pari Pharma spinout Breath raises $46M A round for lung transplant drug-device combo

By Cormac Sheridan
Staff Writer

Wednesday, March 8, 2017

DUBLIN – Breath Therapeutics Holding BV raised €43.5 million in a series A round to undertake phase III trials of a drug-device combo, comprising a nebulizer-delivered, liposome-based formulation of cyclosporine A, in lung transplant patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription